Axsome Therapeutics, Inc.
AXSM
$224.03
$7.563.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.33% | 36.22% | 26.19% | 19.98% | 6.11% |
| Total Depreciation and Amortization | 12.57% | 13.90% | 16.24% | 16.50% | 17.95% |
| Total Amortization of Deferred Charges | -70.42% | -50.64% | -22.46% | 0.98% | 3.03% |
| Total Other Non-Cash Items | -13.07% | -10.69% | -15.76% | 1.31% | -0.62% |
| Change in Net Operating Assets | -86.25% | -168.88% | -113.54% | -167.15% | 217.85% |
| Cash from Operations | 40.22% | 27.26% | 23.85% | 27.98% | 38.61% |
| Capital Expenditure | 48.43% | -77.78% | -77.73% | 10.80% | 16.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 48.43% | -77.78% | -77.73% | 10.80% | 16.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -32,830.21% | -33,648.69% | -39,885.00% | -55,357.88% | -653.37% |
| Issuance of Common Stock | 1.38% | 78.36% | 125.31% | 120.93% | -61.34% |
| Repurchase of Common Stock | -81.03% | -79.91% | -78.40% | -73.97% | -157.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -63.48% | -70.18% | -100.20% | -48.42% | 57.56% |
| Cash from Financing | -14.85% | 75.42% | 127.84% | 132.95% | -68.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.74% | 110.70% | 97.68% | 89.59% | -135.95% |